| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.51▼ | 1.54▼ | 1.56▼ | 5.51▼ | 6.40▼ |
| MA10 | 1.51▼ | 1.58▼ | 1.64▼ | 6.33▼ | 6.81▼ |
| MA20 | 1.53▼ | 1.66▼ | 3.80▼ | 7.20▼ | 8.30▼ |
| MA50 | 1.58▼ | 4.83▼ | 6.02▼ | 7.39▼ | 6.76▼ |
| MA100 | 1.64▼ | 6.08▼ | 6.97▼ | 8.42▼ | 6.76▼ |
| MA200 | 3.27▼ | 7.05▼ | 7.14▼ | 7.41▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.001▼ | 0.206▲ | -0.079▼ | -0.577▼ | -0.640▼ |
| RSI | 24.469▼ | 12.280▼ | 13.405▼ | 21.876▼ | 29.038▼ |
| STOCH | 31.674 | 3.572▼ | 4.346▼ | 34.642 | 25.502 |
| WILL %R | -78.261▼ | -92.424▼ | -96.795▼ | -99.337▼ | -99.459▼ |
| CCI | -205.523▼ | -159.169▼ | -130.936▼ | -240.532▼ | -202.028▼ |
|
Friday, May 08, 2026 04:30 PM
Gene (NASDAQ:ENGN) reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEND trial evaluating detalimogene voroplasmide, or detalimogene, in patients with high-risk ...
|
|
Friday, May 08, 2026 04:05 PM
enGene (NASDAQ:ENGN) reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEND trial evaluating detalimogene voroplasmide, or detalimogene, in patients with high-risk ...
|
|
Friday, May 08, 2026 05:31 AM
enGene Holdings ( (ENGN) ) just unveiled an update.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 08/05/26 | 1.71 | 1.75 | 1.45 | 1.50 | 17,183,794 |
| 07/05/26 | 2.145 | 2.24 | 1.70 | 1.72 | 23,470,705 |
| 06/05/26 | 7.95 | 8.99 | 7.95 | 8.85 | 388,687 |
| 05/05/26 | 7.72 | 8.03 | 7.485 | 7.89 | 416,596 |
| 04/05/26 | 7.19 | 7.765 | 7.19 | 7.61 | 379,947 |
| 01/05/26 | 7.30 | 7.45 | 7.13 | 7.25 | 226,354 |
| 30/04/26 | 7.05 | 7.36 | 7.00 | 7.27 | 154,483 |
| 29/04/26 | 6.86 | 7.25 | 6.86 | 7.04 | 344,513 |
| 28/04/26 | 7.18 | 7.5899 | 6.82 | 6.96 | 1,779,830 |
| 27/04/26 | 7.99 | 8.06 | 7.16 | 7.20 | 845,417 |
|
|
||||
|
|
||||
|
|